Aliases & Classifications for Intermittent Claudication

MalaCards integrated aliases for Intermittent Claudication:

Name: Intermittent Claudication 38 12 55 44 15 73
Amyotrophic Lateral Sclerosis 73
Charcot's Syndrome 12
Charcot Disease 76

Classifications:



External Ids:

Disease Ontology 12 DOID:3669
ICD10 33 I73.9
MeSH 44 D007383
UMLS 73 C0021775

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as amyotrophic lateral sclerosis, is related to critical limb ischemia and peripheral artery disease, and has symptoms including back pain, headache and pain. An important gene associated with Intermittent Claudication is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Angiotensin II and Olmesartan have been mentioned in the context of this disorder. Affiliated tissues include Placenta, endothelial and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Charcot–Marie–Tooth disease (CMT) is one of the hereditary motor and sensory neuropathies, a group of... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 275)
# Related Disease Score Top Affiliating Genes
1 critical limb ischemia 32.1 IL6 VEGFA VWF
2 peripheral artery disease 31.1 ACE CRP IL6 SELP VEGFA
3 carotid stenosis 30.4 ACE CRP SELP
4 limb ischemia 29.7 ACE IL6 VEGFA VWF
5 arteriosclerosis obliterans 29.7 HTR2A IL6 SELP
6 arteriovenous fistula 29.5 APOH IL6
7 systolic heart failure 29.4 ACE CRP IL6
8 polyarteritis nodosa 29.2 APOH CRP IL6
9 arteriosclerosis 28.8 ACE CRP IL6 SELP SERPINE1
10 thrombosis 28.1 APOH F2 SELP SERPINC1 SERPINE1 VWF
11 angina pectoris 28.0 ACE CRP IL6 SERPINC1 SERPINE1 VWF
12 diabetes mellitus 28.0 ACE ALB CRP IL6 SERPINE1 VEGFA
13 diabetes mellitus, noninsulin-dependent 27.6 ACE ALB CRP IL6 SERPINE1 VWF
14 coronary artery anomaly 26.9 ACE CRP IL6 SELP SERPINE1 TNNT2
15 peripheral vascular disease 25.2 ACE ALB CRP F2 IL6 SELP
16 arteries, anomalies of 25.2 ACE ALB CRP F2 IL6 SELP
17 vascular disease 24.3 ACE ALB APOH CRP F2 IL6
18 myocardial infarction 24.2 ACE ALB CRP F2 IL6 SELP
19 amyotrophic lateral sclerosis 1 11.1
20 juvenile amyotrophic lateral sclerosis 10.9
21 infiltrating angiolipoma 10.8 VEGFA VWF
22 hypertensive retinopathy 10.7 ACE VWF
23 heparin-induced thrombocytopenia 10.7 SELP SERPINC1
24 fibrinolytic defect 10.7 SERPINC1 SERPINE1
25 argentine hemorrhagic fever 10.7 SERPINC1 SERPINE1
26 angiodysplasia 10.7 VEGFA VWF
27 sticky platelet syndrome 10.7 SERPINC1 SERPINE1
28 carotid artery thrombosis 10.6 SELP SERPINE1
29 renal artery obstruction 10.6 ACE SERPINC1
30 pyuria 10.6 ALB CRP
31 malignant otitis externa 10.6 CRP F2
32 severe nonproliferative diabetic retinopathy 10.6 ALB VEGFA
33 japanese spotted fever 10.6 CRP SERPINC1
34 active peptic ulcer disease 10.6 F2 VWF
35 chronic thromboembolic pulmonary hypertension 10.5 CRP F2
36 chronic ulcer of skin 10.5 ALB CRP
37 von willebrand disease, type 1 10.5 F2 VWF
38 generalized atherosclerosis 10.5 ACE CRP SELP
39 platelet aggregation, spontaneous 10.5 SELP SERPINC1 VWF
40 ischemic neuropathy 10.5 CRP F2
41 decubitus ulcer 10.5 ALB CRP
42 acroosteolysis 10.5 ALB VEGFA
43 aortic valve disease 1 10.5 ACE CRP VWF
44 hepatoportal sclerosis 10.5 ACE F2
45 coronary restenosis 10.5 ACE SERPINC1
46 aortic valve disease 2 10.5 ACE CRP VWF
47 coronary thrombosis 10.5 SERPINC1 SERPINE1 VWF
48 background diabetic retinopathy 10.4 ALB VEGFA
49 legg-calve-perthes disease 10.4 SELP SERPINC1 SERPINE1
50 systemic scleroderma 10.4 ACE CRP SELP

Comorbidity relations with Intermittent Claudication via Phenotypic Disease Network (PDN):


Acute Cystitis Motor Neuron Disease
Primary Lateral Sclerosis, Adult, 1 Protein-Energy Malnutrition
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Intermittent Claudication:



Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness, asthenia, body temperature changes, cyanosis, edema, eye manifestations, fatigue, oral manifestations, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, skin manifestations, chills, polydipsia, renal colic, hot flushes, urological manifestations, mobility limitation, prodromal symptoms, hypertriglyceridemic waist, medically unexplained symptoms

MGI Mouse Phenotypes related to Intermittent Claudication:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.13 F2 SERPINE1 IL6 TNNT2 ACE SELP
2 homeostasis/metabolism MP:0005376 10.1 F2 SERPINE1 IL6 TNNT2 ACE SELP
3 hematopoietic system MP:0005397 9.97 SERPINC1 F2 SERPINE1 IL6 ACE SELP
4 immune system MP:0005387 9.91 F2 SERPINE1 IL6 ACE SELP SERPINC1
5 digestive/alimentary MP:0005381 9.88 F2 HTR2A IL6 ALB VEGFA VWF
6 liver/biliary system MP:0005370 9.7 SERPINE1 IL6 ACE SELP ALB SERPINC1
7 mortality/aging MP:0010768 9.7 F2 SERPINE1 IL6 TNNT2 ACE SELP
8 renal/urinary system MP:0005367 9.17 SERPINE1 IL6 ACE SELP ALB SERPINC1

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
4
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
5
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
6
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
7
Simvastatin Approved Phase 4,Phase 2,Not Applicable 79902-63-9 54454
8
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2 745-65-3 149351 5280723
9
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
11
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
12
Allopurinol Approved Phase 4 315-30-0 2094
13
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
14
Ramipril Approved Phase 4 87333-19-5 5362129
15
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable 2216-51-5 16666
16
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
17
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
18
Promethazine Approved, Investigational Phase 4 60-87-7 4927
19
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 55142-85-3 5472
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
21
Amlodipine Approved Phase 4 88150-42-9 2162
22
Ezetimibe Approved Phase 4 163222-33-1 150311
23
Thrombin Approved, Investigational Phase 4
24
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
25
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
26
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3 111025-46-8 4829
27
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Not Applicable 274693-27-5 9871419
28
Vorapaxar Approved Phase 4 618385-01-6
29
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
30
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
31
Losartan Approved Phase 4 114798-26-4 3961
32
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
33
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
34
Gliclazide Approved Phase 4 21187-98-4 3475
35
Glyburide Approved Phase 4 10238-21-8 3488
36
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable 58-61-7 60961
37
Acetaminophen Approved Phase 4 103-90-2 1983
38
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
39
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
40
Ranolazine Approved, Investigational Phase 4,Not Applicable 142387-99-3, 95635-55-5 56959
41 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
43
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 59-67-6 938
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 98-92-0 936
45
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
47
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
48
Candesartan Experimental Phase 4 139481-59-7 2541
49
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
50 Adrenergic alpha-Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 425)
# Name Status NCT ID Phase Drugs
1 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Unknown status NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
2 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion Unknown status NCT00407940 Phase 4
3 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis Unknown status NCT02033135 Phase 4
4 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
5 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Unknown status NCT01901224 Phase 4 Metformin 1000 mg;Placebo
6 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
7 Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND) Completed NCT00906022 Phase 4
8 Neurogenic Intermittent Claudication Evaluation Study Completed NCT00905359 Phase 4
9 Evaluation of Cilostazol in Combination With L-Carnitine Completed NCT00822172 Phase 4 cilostazol
10 Intermittent Neurogenic Claudication Treatment With APERIUS® Completed NCT00887744 Phase 4
11 A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4 Limaprost;Pregabalin;Placebo(for Pregabalin);Placebo(for Limaprost)
12 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
13 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
14 Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE) Completed NCT00883246 Phase 4
15 Angioplasty in Peripheral Arterial Disease and Endothelial Function Completed NCT00660634 Phase 4
16 Cilostazol After Lower Extremity Arterial Revascularization Trial Completed NCT02374957 Phase 4 Cilostazol
17 PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents Completed NCT00715416 Phase 4
18 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp) Completed NCT00300690 Phase 4
19 4-EVER : a Trial Investigating the Safety of 4F Endovascular Treatment of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
20 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4 Ramipril
21 DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
22 Lumbar Stenosis Outcomes Research (LUSTOR) Completed NCT00638443 Phase 4 Pregabalin;Diphenhydramine
23 The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD) Completed NCT00189618 Phase 4 Aspirin;Clopidogrel
24 Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions Completed NCT00764777 Phase 4
25 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
26 Intermittent Mechanical Compression For Peripheral Arterial Disease Completed NCT00855673 Phase 4 Control
27 Arterial Inflow and Muscle Ischemia During Calf Stimulation With the Veinoplus Device Completed NCT01592812 Phase 4
28 Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
29 Peripheral Vascular Disease and Nerve Stimulation Completed NCT01942941 Phase 4
30 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study Completed NCT00228384 Phase 4
31 Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors Completed NCT00407537 Phase 4 Amlodipine besylate/atorvastatin calcium single pill combination
32 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed NCT00687076 Phase 4 Ezetimibe;Niaspan;Statin therapy;Aspirin;Clopidogrel;Placebo Niaspan;Placebo Ezetimibe
33 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
34 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Recruiting NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
35 Ramipril Treatment of Claudication Recruiting NCT02842424 Phase 4 Ramipril
36 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Recruiting NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
37 Minuteman Spinal Fusion Implant Versus Surgical Decompression for Lumbar Spinal Stenosis Recruiting NCT01455805 Phase 4
38 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging Recruiting NCT02807779 Phase 4 Dexamethasone infusion
39 Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial Active, not recruiting NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
40 Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease Not yet recruiting NCT03493412 Phase 4 Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin);Placebo
41 The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4 Metformin;Placebo
42 Ticagrelor and Peripheral Arterial Disease Terminated NCT02407314 Phase 4 Aspirin;Aspirin + Ticagrelor
43 Condition of Approval Study Terminated NCT00517751 Phase 4
44 Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant Terminated NCT01057641 Phase 4
45 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
46 Vitamin D and Walking Ability in Patients With Peripheral Artery Occlusive Disease Terminated NCT01559974 Phase 4 Placebo;Cholecalciferol
47 Lumbar Stenosis Outcomes Research II Terminated NCT00652093 Phase 4 opana then darvocet then placebo;opana then placebo then darvocet;placebo then opana then darvocet;Placebo then darvocet then opana;Darvocet then opana then placebo;Darvocet then placebo then opana
48 Effects of X-STOP® Versus Laminectomy Study Withdrawn NCT00558129 Phase 4
49 Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients Withdrawn NCT02121288 Phase 4 Ticagrelor;clopidogrel
50 Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease Withdrawn NCT00657514 Phase 4 Ranolazine;Placebo

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

41
Endothelial, Testes, Bone, Heart, Smooth Muscle, Skeletal Muscle, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 675)
# Title Authors Year
1
Beet the Best? Dietary Inorganic Nitrate to Augment Exercise Training in Lower Extremity Peripheral Artery Disease with Intermittent Claudication. ( 29976553 )
2018
2
Achilles tendon elasticity decreases with intermittent claudication in patients by Acoustic Radiation Force Impulse Imaging (ARFI). ( 29371711 )
2018
3
Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication. ( 29855189 )
2018
4
Primary Stenting of the Superficial Femoral Artery in Patients with Intermittent Claudication Has Durable Effects on Health-Related Quality of Life at 24 Months: Results of a Randomized Controlled Trial. ( 29520431 )
2018
5
WITHDRAWN: Angioplasty (versus non surgical management) for intermittent claudication. ( 29521415 )
2018
6
Combination of endovascular revascularization and supervised exercise therapy for intermittent claudication: a systematic review and meta-analysis. ( 29327569 )
2018
7
Translation and Validation of the Brazilian-Portuguese Short Version of Vascular Quality of Life Questionnaire in Peripheral Artery Disease Patients with Intermittent Claudication Symptoms. ( 29772330 )
2018
8
Extracorporeal shockwave therapy for intermittent claudication: Medium-term outcomes from a double-blind randomised placebo-controlled pilot trial. ( 29722640 )
2018
9
YORwalK: Desiging a Smartphone Exercise Application for People with Intermittent Claudication. ( 29677973 )
2018
10
Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. ( 29627967 )
2018
11
Stenosis of the iliac artery after kidney transplantation as a cause of refractory hypertension and intermittent claudication. ( 29731012 )
2018
12
Exploring physical activity behaviour - needs for and interest in a technology-delivered, home-based exercise programme among patients with intermittent claudication. ( 29144207 )
2018
13
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study. ( 29798770 )
2018
14
Preferred exercise modalities in patients with intermittent claudication. ( 29747787 )
2018
15
Intermittent Claudication due to Cystic Adventitial Disease of the Popliteal Artery: Importance of Multiple Imaging Modalities. ( 29625518 )
2018
16
Joint moment strategies during stair descent in patients with peripheral arterial disease and intermittent claudication. ( 29625411 )
2018
17
Risk of major amputation in patients with intermittent claudication undergoing early revascularization. ( 29566427 )
2018
18
Endovascular revascularisation versus conservative management for intermittent claudication. ( 29518253 )
2018
19
Use of Telehealth as a New Model for Following Intermittent Claudication and Promoting Patient Expertise. ( 29323628 )
2018
20
Cardiovascular and all-cause mortality in patients with intermittent claudication and critical limb ischaemia. ( 29116654 )
2018
21
Systematic review and meta-analysis of high-pressure intermittent limb compression for the treatment of intermittent claudication. ( 29389425 )
2018
22
Reversal of Lower-Extremity Intermittent Claudication and Rest Pain by Hydration. ( 29481920 )
2018
23
Home-based exercise for elderly patients with intermittent claudication limited by osteoarticular disorders - feasibility and effectiveness of a low-intensity programme. ( 29463192 )
2018
24
Amputation Rates, Mortality, and Pre-operative Comorbidities in Patients Revascularised for Intermittent Claudication or Critical Limb Ischaemia: A Population Based Study. ( 28797662 )
2017
25
Exercise training for intermittent claudication. ( 28874320 )
2017
26
Supervised Exercise Therapy for Intermittent Claudication Is Increasingly Endorsed by Dutch Vascular Surgeons. ( 28893711 )
2017
27
Intravenous alprostadil treatment compared to oral pentoxifylline treatment in outpatients with intermittent claudication - results of a randomised clinical trial. ( 28558485 )
2017
28
Intermittent Claudication ( 28613529 )
2017
29
A Case of Polyarteritis Nodosa Presenting as Rapidly Progressing Intermittent Claudication of Right Leg. ( 29109739 )
2017
30
Exercise for intermittent claudication. ( 29278423 )
2017
31
Centers for Medicare and Medicaid Services Policy Regarding Supervised Exercise for Patients With Intermittent Claudication: The Good, the Bad, and the Ugly. ( 29191119 )
2017
32
Improved Adherence to a Stepped-care Model Reduces Costs of Intermittent Claudication Treatment in The Netherlands. ( 28539212 )
2017
33
Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. ( 27763685 )
2017
34
A Rare Case of Intermittent Claudication Associated with Impaired Arterial Vasodilation. ( 29435381 )
2017
35
Choosing the individual rehabilitation program for patients with intermittent claudication. ( 28691674 )
2017
36
Two otherwise healthy young brothers present with intermittent claudication, just a coincidence? ( 28684644 )
2017
37
User Preferences for Mobile Health Interventions: A Survey Among Intermittent Claudication Patients and Their Physical Therapists. ( 28893710 )
2017
38
Long-term results with percutaneous interspinous process devices in the treatment of neurogenic intermittent claudication. ( 29354740 )
2017
39
Unloading shoes for intermittent claudication: a randomised crossover trial. ( 29179693 )
2017
40
Intermittent claudication and severe renal artery stenosis are independently associated in hypertensive patients referred for renal arteriography. ( 28793000 )
2017
41
A feasibility double-blind randomized placebo-controlled trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication. ( 28943002 )
2017
42
Quality of life in patients with intermittent claudication. ( 28529410 )
2017
43
Patients With Intermittent Claudication and Chronic Widespread Pain Improves in Health-Related Quality of Life After Invasive but Not After Noninvasive Treatment. ( 29308018 )
2017
44
Identifying content gaps in health status measures for intermittent claudication using the International Classification of Functioning, Disability and Health. ( 29074112 )
2017
45
A systematic review of muscle morphology and function in intermittent claudication. ( 28822657 )
2017
46
The Effect of Structured Patient Education on Physical Activity in Patients with Peripheral Arterial Disease and Intermittent Claudication: A Systematic Review. ( 28528678 )
2017
47
"Intermittent claudication a real pain in the calf"-Patient experience of diagnosis and treatment with a supervised exercise program. ( 28838587 )
2017
48
Baseline assessment and comparison of arterial anatomy, hyperemic flow, and skeletal muscle perfusion in peripheral artery disease: The Cardiovascular Cell Therapy Research Network "Patients with Intermittent Claudication Injected with ALDH Bright Cells" (CCTRN PACE) study. ( 27979038 )
2017
49
Functional electrical stimulation improves quality of life by reducing intermittent claudication. ( 28595744 )
2017
50
Reproducibility of heart rate recovery in patients with intermittent claudication. ( 28752607 )
2017

Variations for Intermittent Claudication

Copy number variations for Intermittent Claudication from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107025 17 11200000 22100000 Microduplication Charcot

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.92 ACE ALB APOH CRP F2 SERPINC1
2 extracellular region GO:0005576 9.65 ACE ALB APOH CRP F2 IL6
3 endoplasmic reticulum lumen GO:0005788 9.56 ALB F2 IL6 SERPINC1
4 platelet alpha granule lumen GO:0031093 9.46 ALB SERPINE1 VEGFA VWF
5 extracellular space GO:0005615 9.32 ACE ALB APOH CRP F2 IL6

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 F2 IL6 SERPINE1 VEGFA
2 cellular protein metabolic process GO:0044267 9.76 ALB F2 IL6 SERPINC1
3 platelet activation GO:0030168 9.73 F2 IL6 VWF
4 defense response to Gram-negative bacterium GO:0050829 9.7 IL6 SELP SERPINE1
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 HTR2A IL6 VEGFA
6 positive regulation of JAK-STAT cascade GO:0046427 9.58 F2 IL6
7 hemostasis GO:0007599 9.58 F2 SERPINC1 VWF
8 fibrinolysis GO:0042730 9.57 F2 SERPINE1
9 negative regulation of blood coagulation GO:0030195 9.55 APOH SERPINE1
10 positive regulation of leukocyte migration GO:0002687 9.54 SELP VEGFA
11 acute-phase response GO:0006953 9.54 CRP F2 IL6
12 blood coagulation, intrinsic pathway GO:0007597 9.5 APOH F2 VWF
13 neutrophil mediated immunity GO:0002446 9.49 ACE IL6
14 negative regulation of lipid storage GO:0010888 9.48 CRP IL6
15 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.43 ACE VEGFA
16 positive regulation of blood coagulation GO:0030194 9.43 APOH F2 SERPINE1
17 regulation of blood coagulation GO:0030193 9.33 APOH F2 SERPINC1
18 negative regulation of fibrinolysis GO:0051918 9.13 APOH F2 SERPINE1
19 platelet degranulation GO:0002576 9.1 ALB APOH SELP SERPINE1 VEGFA VWF

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB APOH CRP SERPINC1 VEGFA VWF
2 growth factor activity GO:0008083 9.5 F2 IL6 VEGFA
3 protease binding GO:0002020 9.43 SERPINC1 SERPINE1 VWF
4 drug binding GO:0008144 9.13 ACE ALB HTR2A
5 heparin binding GO:0008201 9.02 APOH F2 SELP SERPINC1 VEGFA

Sources for Intermittent Claudication

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....